Contact
searchSearch
HMP Global
Login

Multiple Myeloma Resource Center

News
Lenalidomide Before Apheresis Enhances CAR T-Cell Fitness in Newly Diagnosed Multiple Myeloma
12/19/2025
Grace Taylor, MS, MA
Pre-apheresis lenalidomide significantly improved T-cell fitness and pharmacodynamic activity of idecabtagene vicleucel (ide-cel) in newly diagnosed multiple myeloma (NDMM), according to a KarMMa-2 cross-cohort analysis.
Pre-apheresis lenalidomide significantly improved T-cell fitness and pharmacodynamic activity of idecabtagene vicleucel (ide-cel) in newly diagnosed multiple myeloma (NDMM), according to a KarMMa-2 cross-cohort analysis.
Pre-apheresis lenalidomide...
12/19/2025
Journal of Clinical Pathways
Conference Coverage
Breakthrough Advances in Immunotherapy Transform Care in Leukemia, Lymphoma, and Myeloma
12/17/2025
Grace Taylor, MS, MA
Immunotherapy advancements across leukemia, lymphoma, and myeloma are reshaping treatment pathways, demonstrating deeper responses, improved survival, and expanding earlier-line options for patients.
Immunotherapy advancements across leukemia, lymphoma, and myeloma are reshaping treatment pathways, demonstrating deeper responses, improved survival, and expanding earlier-line options for patients.
Immunotherapy advancements...
12/17/2025
Journal of Clinical Pathways
Original Research
Outpatient Care Model for Teclistamab Step-Up Dosing for the Treatment of Relapsed or Refractory Multiple Myeloma at OneOncology: Insights From a Managed Network of Independent Physician-Owned Community-Based Oncology Practices
12/15/2025
Lisa Raff, PharmD; Rozanne Wilson, PhD; Richard Murphy, BA; Amal Jamaleddine, BA; Nicole Bariahtaris, BA; Meaghan Roach, MPH
A community-derived playbook from OneOncology outlines practical strategies for delivering teclistamab step-up dosing in outpatient settings, enabling safer, more convenient access for patients.
A community-derived playbook from OneOncology outlines practical strategies for delivering teclistamab step-up dosing in outpatient settings, enabling safer, more convenient access for patients.
A community-derived playbook...
12/15/2025
Journal of Clinical Pathways
News
Cancer Predisposition Genes Found in 1 in 10 Patients With Multiple Myeloma
12/17/2024
Jolynn Tumolo
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients...
12/17/2024
Journal of Clinical Pathways
News
Model Predicts Outcomes After BCMA CAR-T in Patients With RRMM
12/10/2024
Jolynn Tumolo
Researchers have created a model that uses disease-, treatment-, and inflammation-related variables to predict outcomes after anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T therapy (CAR-T) in patients with...
Researchers have created a model that uses disease-, treatment-, and inflammation-related variables to predict outcomes after anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T therapy (CAR-T) in patients with...
Researchers have created a model...
12/10/2024
Journal of Clinical Pathways
Hamza Hashmi, MD
Videos
Recent Advancements in Myeloma Treatment Changing the Standard of Care
04/04/2024

Featuring Hamza Hashmi, MD

Featuring Hamza Hashmi, MD
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan...
04/04/2024
Journal of Clinical Pathways
News
Benefit of Adding Daratumumab to Bortezomib, Lenalidomide, and Dexamethasone Therapy for Transplant-Eligible Patients With Newly Diagnosed MM
03/05/2024

Jordan Kadish

Jordan Kadish
According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...
According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...
According to a phase 3 trial,...
03/05/2024
Oncology
From Oncology
News
Progression-Free Survival Benefits of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone For Multiple Myeloma
01/31/2024
Emry Lloyd
Daratumumab, bortezomib, lenalidomide, and dexamethasone have shown significant results in progression-free survival rates for patients with newly diagnosed multiple myeloma.
Daratumumab, bortezomib, lenalidomide, and dexamethasone have shown significant results in progression-free survival rates for patients with newly diagnosed multiple myeloma.
Daratumumab, bortezomib,...
01/31/2024
Journal of Clinical Pathways
News
Efficacy in Clinical Trials vs Effectiveness in the Real World for Multiple Myeloma Treatment Regimens
01/18/2024
Grace Taylor, MS, MA
A study by Kelvin Chan, MD, PhD, and colleagues compared the efficacy of registrational randomized controlled trials vs the effectiveness in the real world for patients receiving standard of care regimens for multiple myeloma.
A study by Kelvin Chan, MD, PhD, and colleagues compared the efficacy of registrational randomized controlled trials vs the effectiveness in the real world for patients receiving standard of care regimens for multiple myeloma.
A study by Kelvin Chan, MD, PhD,...
01/18/2024
Journal of Clinical Pathways
News
Clonal Hematopoiesis Associated With High Risk of CVD Among Patients With MM Undergoing HCT
11/29/2023
Amber Denham
Clonal hematopoiesis of indeterminate potential was both significantly and independently associated with risk of cardiovascular disease among patients with multiple myeloma undergoing hematopoietic cell transplant, according to a...
Clonal hematopoiesis of indeterminate potential was both significantly and independently associated with risk of cardiovascular disease among patients with multiple myeloma undergoing hematopoietic cell transplant, according to a...
Clonal hematopoiesis of...
11/29/2023
Oncology
From Oncology
Francesco Maura, MD
Videos
Genomic Mechanism of Resistance Among Patients With Newly Diagnosed Multiple Myeloma Treated With Immunotherapy
01/19/2023
Francesco Maura, MD, investigated the use of whole genome sequencing to help predict patients with NDMM who may fail to achieve sustained minimal residual disease negativity through unknown resistance mechanisms.
Francesco Maura, MD, investigated the use of whole genome sequencing to help predict patients with NDMM who may fail to achieve sustained minimal residual disease negativity through unknown resistance mechanisms.
Francesco Maura, MD,...
01/19/2023
Journal of Clinical Pathways

Expert Insights

Hamza Hashmi, MD
Videos
Recent Advancements in Myeloma Treatment Changing the Standard of Care
04/04/2024

Featuring Hamza Hashmi, MD

Featuring Hamza Hashmi, MD
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan...
04/04/2024
Journal of Clinical Pathways
Francesco Maura, MD
Videos
Genomic Mechanism of Resistance Among Patients With Newly Diagnosed Multiple Myeloma Treated With Immunotherapy
01/19/2023
Francesco Maura, MD, investigated the use of whole genome sequencing to help predict patients with NDMM who may fail to achieve sustained minimal residual disease negativity through unknown resistance mechanisms.
Francesco Maura, MD, investigated the use of whole genome sequencing to help predict patients with NDMM who may fail to achieve sustained minimal residual disease negativity through unknown resistance mechanisms.
Francesco Maura, MD,...
01/19/2023
Journal of Clinical Pathways
Robert Rifkin, MD
Videos
Utilizing Real-World Data to Assess the Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma
12/21/2022
Robert Rifkin, MD, discusses his abstract presented at the 64th ASH Annual Meeting on utilizing data from the Connect MM Registry, the oldest and largest myeloma disease-specific registry, to understand changes in the patterns of multiple...
Robert Rifkin, MD, discusses his abstract presented at the 64th ASH Annual Meeting on utilizing data from the Connect MM Registry, the oldest and largest myeloma disease-specific registry, to understand changes in the patterns of multiple...
Robert Rifkin, MD, discusses his...
12/21/2022
Journal of Clinical Pathways
Thomas Martin, MD, UCSF
Interview
Isatuximab Plus Carfilzomib and Dexamethasone for Relapsed MM: Results From the IKEMA Trial
03/30/2022
Thomas Martin, MD, discusses results from the IKEMA trial, which explored the addition of isatuximab to carfilzomib and dexamethasone for patients with relapsed MM.
Thomas Martin, MD, discusses results from the IKEMA trial, which explored the addition of isatuximab to carfilzomib and dexamethasone for patients with relapsed MM.
Thomas Martin, MD, discusses...
03/30/2022
Journal of Clinical Pathways
Christopher Kim, Amgen
Videos
Real-World Treatments and Outcomes of Triple-Class Relapsed or Refractory MM
01/11/2022
Christopher Kim, PhD, MPH, discusses findings from a study which evaluated treatment and outcomes among patients with triple-class relapsed or refractory MM in US community practice.
Christopher Kim, PhD, MPH, discusses findings from a study which evaluated treatment and outcomes among patients with triple-class relapsed or refractory MM in US community practice.
Christopher Kim, PhD, MPH,...
01/11/2022
Journal of Clinical Pathways
Videos
All4Cure: Patient Data Aggregate Platform for Collaborative Multiple Myeloma Care
03/05/2021
Tony Blau, MD, Founder and CEO, provides a demonstration of All4Cure, discusses the vision and need for the platform, and describes its ability to improve patient care.
Tony Blau, MD, Founder and CEO, provides a demonstration of All4Cure, discusses the vision and need for the platform, and describes its ability to improve patient care.
Tony Blau, MD, Founder and CEO,...
03/05/2021
Journal of Clinical Pathways
Videos
IRd vs Placebo-Rd for Patients With Newly-Diagnosed MM
12/20/2020
12/20/2020
Journal of Clinical Pathways
Videos
Real-World Comparison of DRd and DPd for Relapsed/Refractory MM
12/09/2020
Muhamad Alhaj Moustafa, MD, presents findings from a study comparing daratumumab plus lenalidomide and dexamethasone (DRd) vs daratumumab plus pomalidomide and dexamethasone (DPd) for lenalidomide-exposed patients with relapsed or refractory...
Muhamad Alhaj Moustafa, MD, presents findings from a study comparing daratumumab plus lenalidomide and dexamethasone (DRd) vs daratumumab plus pomalidomide and dexamethasone (DPd) for lenalidomide-exposed patients with relapsed or refractory...
Muhamad Alhaj Moustafa, MD,...
12/09/2020
Journal of Clinical Pathways
ENGAGING EXPERTS
Comparative Effectiveness of KRd Versus VRd for Newly Diagnosed MM
08/27/2020
08/27/2020
Journal of Clinical Pathways
Guest Blog
Navigating the Labyrinth of Multiple Myeloma Treatment
04/24/2018
Thomas Marsland, MD
Thomas Marsland, MD, medical oncology, St Joseph Health (Petaluma, CA), discusses the many considerations related to initial therapy, transplantation, maintenance, and salvage therapy for patients with multiple myeloma.
Thomas Marsland, MD, medical oncology, St Joseph Health (Petaluma, CA), discusses the many considerations related to initial therapy, transplantation, maintenance, and salvage therapy for patients with multiple myeloma.
Thomas Marsland, MD, medical...
04/24/2018
Journal of Clinical Pathways
Olivia Lynch
Interview
Where Access Breaks Down: Uncovering Persistent Disparities in Early-Stage Lung Cancer Treatment
04/21/2026
Olivia Lynch, MD, MPH
A guest expert shares research findings about persistent racial disparities in access to curative treatment for early-stage lung cancer, pointing to systemic barriers that arise before patients ever reach the operating room.
A guest expert shares research findings about persistent racial disparities in access to curative treatment for early-stage lung cancer, pointing to systemic barriers that arise before patients ever reach the operating room.
A guest expert shares research...
04/21/2026
Journal of Clinical Pathways
NSCLC
Videos
Bridging Clinical Trials and Real-World Evidence in ALK-Positive Non–Small Cell Lung Cancer Treatment: Part 2
03/24/2026
Rahul Mudumba, PhD, MHS
Rahul Mudumba discusses how real-world evidence can refine value-based pathway decisions for ALK-positive non–small cell lung cancer (NSCLC) and previews new research on first-line ALK inhibitor effectiveness.
Rahul Mudumba discusses how real-world evidence can refine value-based pathway decisions for ALK-positive non–small cell lung cancer (NSCLC) and previews new research on first-line ALK inhibitor effectiveness.
Rahul Mudumba discusses how...
03/24/2026
Journal of Clinical Pathways
NSCLC
Videos
Bridging Clinical Trials and Real-World Evidence in ALK-Positive Non–Small Cell Lung Cancer Treatment
03/24/2026
Rahul Mudumba, PhD, MHS
In this interview, Rahul Mudumba discusses findings from his study on real-world treatment patterns and time-to-treatment discontinuation among patients with advanced ALK-positive non–small cell lung cancer.
In this interview, Rahul Mudumba discusses findings from his study on real-world treatment patterns and time-to-treatment discontinuation among patients with advanced ALK-positive non–small cell lung cancer.
In this interview, Rahul Mudumba...
03/24/2026
Journal of Clinical Pathways
Quality Outlook
Measuring Justice in Breast Cancer Screening: A Bioethical Framework for Analyzing Quality Measures
03/10/2026
Nandita Ammanamanchi, BA; Rachel Delinger, MPH; David Blaisdell, BA; Tom Valuck, MD, JD
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality...
03/10/2026
Journal of Clinical Pathways
Ovarian cancer, Rosella trial
Videos
Advancing Treatment in Platinum-Resistant Ovarian Cancer: Clinical Impact of the ROSELLA Trial
03/03/2026
Robert L. Colemen, MD, FACOG, FACS
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses...
03/03/2026
Journal of Clinical Pathways
Non-small cell lung cancer, NSCLC
Videos
Examining Equity Gaps in Immune Checkpoint Inhibitor Trials for NSCLC
02/25/2026
Adam Barsouk, MD
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses...
02/25/2026
Journal of Clinical Pathways
Quality Outlook
The Rising and Setting of Health Equity
02/24/2026
David Sloan, PhD; Tom Valuck, MD, JD
After years of integrating health equity into value-based care, recent federal policy changes are reshaping how disparities are measured, reported, and addressed across the US health system.
After years of integrating health equity into value-based care, recent federal policy changes are reshaping how disparities are measured, reported, and addressed across the US health system.
After years of integrating...
02/24/2026
Journal of Clinical Pathways
JJN
Interview
NSCLC Clinical Pathways in the Era of Molecular Complexity, AI, and Value-Based Care
02/20/2026
Jorge J. Nieva, MD
In this interview, a guest expert discusses how clinical pathways in EGFR- and ALK-mutated non-small cell lung cancer (NSCLC) must adapt to growing molecular complexity, integrate emerging technologies such as artificial intelligence and...
In this interview, a guest expert discusses how clinical pathways in EGFR- and ALK-mutated non-small cell lung cancer (NSCLC) must adapt to growing molecular complexity, integrate emerging technologies such as artificial intelligence and...
In this interview, a guest...
02/20/2026
Journal of Clinical Pathways
NSCLC, non-small cell lung cancer
Interview
Reflex NGS and PD-L1 Testing Streamlines Biomarker Turnaround and Treatment Planning in Resectable NSCLC
01/27/2026
Tina Edmonston, MD; David D. Shersher, MD
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David...
01/27/2026
Journal of Clinical Pathways
Olalekan Oluwole, MD, MBBS
Conference Coverage
Time and Travel Impact of CAR T-Cell vs Bispecific Antibody Therapy for Patients With R/R DLBCL: Real-World Analysis
01/26/2026
Olalekan O. Oluwole
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS,...
01/26/2026
Oncology

Newsfeed

News
Lenalidomide Before Apheresis Enhances CAR T-Cell Fitness in Newly Diagnosed Multiple Myeloma
12/19/2025
Grace Taylor, MS, MA
Pre-apheresis lenalidomide significantly improved T-cell fitness and pharmacodynamic activity of idecabtagene vicleucel (ide-cel) in newly diagnosed multiple myeloma (NDMM), according to a KarMMa-2 cross-cohort analysis.
Pre-apheresis lenalidomide significantly improved T-cell fitness and pharmacodynamic activity of idecabtagene vicleucel (ide-cel) in newly diagnosed multiple myeloma (NDMM), according to a KarMMa-2 cross-cohort analysis.
Pre-apheresis lenalidomide...
12/19/2025
Journal of Clinical Pathways
Conference Coverage
Breakthrough Advances in Immunotherapy Transform Care in Leukemia, Lymphoma, and Myeloma
12/17/2025
Grace Taylor, MS, MA
Immunotherapy advancements across leukemia, lymphoma, and myeloma are reshaping treatment pathways, demonstrating deeper responses, improved survival, and expanding earlier-line options for patients.
Immunotherapy advancements across leukemia, lymphoma, and myeloma are reshaping treatment pathways, demonstrating deeper responses, improved survival, and expanding earlier-line options for patients.
Immunotherapy advancements...
12/17/2025
Journal of Clinical Pathways
News
Cancer Predisposition Genes Found in 1 in 10 Patients With Multiple Myeloma
12/17/2024
Jolynn Tumolo
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients...
12/17/2024
Journal of Clinical Pathways
News
Model Predicts Outcomes After BCMA CAR-T in Patients With RRMM
12/10/2024
Jolynn Tumolo
Researchers have created a model that uses disease-, treatment-, and inflammation-related variables to predict outcomes after anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T therapy (CAR-T) in patients with...
Researchers have created a model that uses disease-, treatment-, and inflammation-related variables to predict outcomes after anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T therapy (CAR-T) in patients with...
Researchers have created a model...
12/10/2024
Journal of Clinical Pathways
Hamza Hashmi, MD
Videos
Recent Advancements in Myeloma Treatment Changing the Standard of Care
04/04/2024

Featuring Hamza Hashmi, MD

Featuring Hamza Hashmi, MD
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan...
04/04/2024
Journal of Clinical Pathways
News
Benefit of Adding Daratumumab to Bortezomib, Lenalidomide, and Dexamethasone Therapy for Transplant-Eligible Patients With Newly Diagnosed MM
03/05/2024

Jordan Kadish

Jordan Kadish
According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...
According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...
According to a phase 3 trial,...
03/05/2024
Oncology
News
Progression-Free Survival Benefits of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone For Multiple Myeloma
01/31/2024
Emry Lloyd
Daratumumab, bortezomib, lenalidomide, and dexamethasone have shown significant results in progression-free survival rates for patients with newly diagnosed multiple myeloma.
Daratumumab, bortezomib, lenalidomide, and dexamethasone have shown significant results in progression-free survival rates for patients with newly diagnosed multiple myeloma.
Daratumumab, bortezomib,...
01/31/2024
Journal of Clinical Pathways
News
Efficacy in Clinical Trials vs Effectiveness in the Real World for Multiple Myeloma Treatment Regimens
01/18/2024
Grace Taylor, MS, MA
A study by Kelvin Chan, MD, PhD, and colleagues compared the efficacy of registrational randomized controlled trials vs the effectiveness in the real world for patients receiving standard of care regimens for multiple myeloma.
A study by Kelvin Chan, MD, PhD, and colleagues compared the efficacy of registrational randomized controlled trials vs the effectiveness in the real world for patients receiving standard of care regimens for multiple myeloma.
A study by Kelvin Chan, MD, PhD,...
01/18/2024
Journal of Clinical Pathways
News
Clonal Hematopoiesis Associated With High Risk of CVD Among Patients With MM Undergoing HCT
11/29/2023
Amber Denham
Clonal hematopoiesis of indeterminate potential was both significantly and independently associated with risk of cardiovascular disease among patients with multiple myeloma undergoing hematopoietic cell transplant, according to a...
Clonal hematopoiesis of indeterminate potential was both significantly and independently associated with risk of cardiovascular disease among patients with multiple myeloma undergoing hematopoietic cell transplant, according to a...
Clonal hematopoiesis of...
11/29/2023
Oncology
Conference Coverage
BME Signatures at Baseline and During Treatment Enable Risk Stratifications of Patients With Multiple Myeloma
12/12/2022
Craig Ostroff
In a presentation at the 64th ASH Annual Meeting and Exposition, Simon Steiger, PhD, and colleagues presented a longitudinal study in which they attempted to associate BME samples with multiple myeloma cytogenic and molecular subgroups.
In a presentation at the 64th ASH Annual Meeting and Exposition, Simon Steiger, PhD, and colleagues presented a longitudinal study in which they attempted to associate BME samples with multiple myeloma cytogenic and molecular subgroups.
In a presentation at the 64th...
12/12/2022
Journal of Clinical Pathways
News
How Age, Comorbidities, and Race Influence Cancer Treatment in Older Patients
05/05/2026
Rebecca Amrick
Using the US Surveillance, Epidemiology, and End Results (SEER)-Medicare linkage database, a study identified potential gaps in geriatric oncology care among Black and Hispanic patients, older age groups, and patients with multimorbidity.
Using the US Surveillance, Epidemiology, and End Results (SEER)-Medicare linkage database, a study identified potential gaps in geriatric oncology care among Black and Hispanic patients, older age groups, and patients with multimorbidity.
Using the US Surveillance,...
05/05/2026
Journal of Clinical Pathways
News
Liquid Biopsies Show Promise but Face Key Challenges in Older Adults
04/29/2026
Lisa Kuhns, PhD, MD
Liquid biopsies hold promise for transforming cancer care in older adults—but age-related biological changes may complicate their accuracy and clinical use.
Liquid biopsies hold promise for transforming cancer care in older adults—but age-related biological changes may complicate their accuracy and clinical use.
Liquid biopsies hold promise for...
04/29/2026
Journal of Clinical Pathways
News
Just Released: 2026 Clinical Pathways Congress Agenda
04/23/2026
Danielle Sposato
Join us November 10–11, 2026 at the Four Seasons Hotel Boston as we bring together leaders across the pathways ecosystem for two days focused on turning strategy into action.
Join us November 10–11, 2026 at the Four Seasons Hotel Boston as we bring together leaders across the pathways ecosystem for two days focused on turning strategy into action.
Join us November 10–11, 2026 at...
04/23/2026
Journal of Clinical Pathways
News
Proactive Outreach for Smoking Cessation Treatment Shows Potential for Patients With Cancer
04/17/2026
Rebecca Amrick
A proactive smoking cessation program for patients with cancer shows high engagement and satisfaction among participants, but low enrollment highlights ongoing challenges with patient identification and outreach.
A proactive smoking cessation program for patients with cancer shows high engagement and satisfaction among participants, but low enrollment highlights ongoing challenges with patient identification and outreach.
A proactive smoking cessation...
04/17/2026
Journal of Clinical Pathways
News
Interventional Radiology Leads Multidisciplinary Care in Liver Cancer Treatment
04/15/2026
Lisa Kuhns, PhD, MD
Research suggests that interventional radiology is central to hepatocellular carcinoma (HCC) care at all stages.
Research suggests that interventional radiology is central to hepatocellular carcinoma (HCC) care at all stages.
Research suggests that...
04/15/2026
Journal of Clinical Pathways
News
Short-Duration Venetoclax Plus Decitabine Shows Comparable AML Outcomes
04/09/2026
Grace Taylor, MS, MA
A shortened 10-day venetoclax regimen combined with decitabine delivers comparable remission rates with fewer infections in older patients with newly diagnosed acute myeloid leukemia (AML).
A shortened 10-day venetoclax regimen combined with decitabine delivers comparable remission rates with fewer infections in older patients with newly diagnosed acute myeloid leukemia (AML).
A shortened 10-day venetoclax...
04/09/2026
Journal of Clinical Pathways
News
FDA Approves Relacorilant Plus Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer
04/08/2026
Grace Taylor, MS, MA
The US Food and Drug Administration's (FDA) approval of relacorilant plus nab-paclitaxel offers a new survival-improving option for patients with platinum-resistant ovarian cancer following prior bevacizumab therapy.
The US Food and Drug Administration's (FDA) approval of relacorilant plus nab-paclitaxel offers a new survival-improving option for patients with platinum-resistant ovarian cancer following prior bevacizumab therapy.
The US Food and Drug...
04/08/2026
Journal of Clinical Pathways
Conference Coverage
Community-Engaged Strategies Reduce Cancer Care Delays and Advance Health Equity
03/27/2026
Hannah Musick
A nationwide, community-engaged cancer care initiative shows that coordinated workflows, patient navigation, and targeted social determinants of health interventions can improve treatment adherence, patient satisfaction, and equity in access...
A nationwide, community-engaged cancer care initiative shows that coordinated workflows, patient navigation, and targeted social determinants of health interventions can improve treatment adherence, patient satisfaction, and equity in access...
A nationwide, community-engaged...
03/27/2026
Journal of Clinical Pathways
Conference Coverage
Targeted Education Improves Cancer Pain Management in Community Hospitals
03/27/2026
Grace Taylor, MS, MA
A brief, National Comprehensive Cancer Network (NCCN)-guided educational session markedly improved hospitalists’ confidence and evidence-based cancer pain management practices in a community hospital setting.
A brief, National Comprehensive Cancer Network (NCCN)-guided educational session markedly improved hospitalists’ confidence and evidence-based cancer pain management practices in a community hospital setting.
A brief, National Comprehensive...
03/27/2026
Journal of Clinical Pathways
Conference Coverage
SEER Analysis Highlights Risk Factors for Advanced DLBCL at Diagnosis
03/27/2026
Grace Taylor, MS, MA
A large SEER-based analysis shows that logistic regression can accurately predict advanced-stage diffuse large B-cell lymphoma (DLBCL) at diagnosis, identifying key demographic and clinical risk factors to guide targeted screening and earlier...
A large SEER-based analysis shows that logistic regression can accurately predict advanced-stage diffuse large B-cell lymphoma (DLBCL) at diagnosis, identifying key demographic and clinical risk factors to guide targeted screening and earlier...
A large SEER-based analysis...
03/27/2026
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Safety and Efficacy of Belantamab Mafodotin for Relapsed/Refractory MM
04/06/2022
True or False: In the real-world setting, belantamab mafodotin demonstrates comparable responses and toxicities in patients with multiple myeloma to those seen in clinical trials.
True or False: In the real-world setting, belantamab mafodotin demonstrates comparable responses and toxicities in patients with multiple myeloma to those seen in clinical trials.
True or False: In the real-world...
04/06/2022
Journal of Clinical Pathways
Quiz
Quiz: Consolidation and Maintenance vs Maintenance Alone for Newly Diagnosed MM
12/01/2021
True or False: Consolidation treatment with bortezomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance may improve progression-free survival and depth of response, compared to no consolidation in patients with newly...
True or False: Consolidation treatment with bortezomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance may improve progression-free survival and depth of response, compared to no consolidation in patients with newly...
True or False: Consolidation...
12/01/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Belantamab Mafodotin for Relapsed/Refractory MM
10/14/2021
True or False: Belantamab mafodotin is cost-effective compared to selinexor plus dexamethasone, for patients with relapsed/refractory multiple myeloma who have received 4 or more therapies.
True or False: Belantamab mafodotin is cost-effective compared to selinexor plus dexamethasone, for patients with relapsed/refractory multiple myeloma who have received 4 or more therapies.
True or False: Belantamab...
10/14/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Daratumumab for MM
09/09/2021
True or False: Adding daratumumab to bortezomib, melphalan, and prednisone for the treatment of newly diagnosed multiple myeloma is not considered cost-effective.
True or False: Adding daratumumab to bortezomib, melphalan, and prednisone for the treatment of newly diagnosed multiple myeloma is not considered cost-effective.
True or False: Adding...
09/09/2021
Journal of Clinical Pathways
Quiz
Quiz: Daratumumab Among Patients With MM
07/19/2021
True or False: Daratumumab-based regimens are an effective treatment option for multiple myeloma across all lines therapy, presenting the strongest response in the first-line setting.
True or False: Daratumumab-based regimens are an effective treatment option for multiple myeloma across all lines therapy, presenting the strongest response in the first-line setting.
True or False: Daratumumab-based...
07/19/2021
Journal of Clinical Pathways
Quiz
Quiz: DRd vs Rd for Newly Diagnosed MM
03/12/2021
03/12/2021
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use